Bacterial survival in radiopharmaceutical solutions: a critical impact on current practices

Springer Science and Business Media LLC
Julien Leenhardt1, Luc Choisnard2, M. Plasse3, Valérie Ardisson4, Nicolas De Leiris1, Loïc Djaileb1, Pierrick Bedouch3, Marie-Dominique Brunet1
1Univ. Grenoble Alpes, INSERM, CHU Grenoble Alpes, LRB, 38000, Grenoble, France
2Univ. Grenoble Alpes, Domaine Universitaire de Grenoble, DPM, UMR CNRS 5063, 470, rue de la Chimie, 38400, Saint Martin d’Hères, France
3Univ. Grenoble Alpes, CHU Grenoble Alpes, Pharmacy , 38000, Grenoble, France
4Cancer Institute Eugène Marquis, Department of Nuclear Medicine, 35000, Rennes, France.

Tóm tắt

Abstract Background The aim of this brief communication is to highlight the potential bacteriological risk linked to the processes control of radiopharmaceutical preparations made in a radiopharmacy laboratory. Survival rate of Pseudomonas aeruginosa (ATCC: 27853) or Staphylococcus aureus (ATCC: 25923) or Staphylococcus epidermidis (ATCC: 1228) in multidose technetium-99 m solution was studied. Results Depending on the nature and level of contamination by pathogenic bacteria, the lethal effect of radioactivity is not systematically observed. We found that P. aeruginosa was indeed affected by radioactivity. However, this was not the case for S. epidermidis, as the quantity of bacteria found in both solutions (radioactive and non-radioactive) was rapidly reduced, probably due to a lack of nutrients. Finally, the example of S. aureus is an intermediate case where we observed that high radioactivity affected the bacteria, as did the absence of nutrients in the reaction medium. The results were discussed in the light of current practices on the sterility test method, which recommends waiting for radioactivity to decay before carrying out the sterility test. Conclusion In terms of patient safety, the results run counter to current practice and the latest EANM recommendation of 2021 that radiopharmaceutical preparations should be decayed before sterility testing.

Từ khóa


Tài liệu tham khảo

Brown S, Baker MH. The sterility testing of dispensed radiopharmaceuticals. Nucl Med Commun. 1986;7:327–36.

Dumont A, Rizzo-Padoin N, Jourdain J-R, et al. Exercice de la radiopharmacie: spécificités et particularités. J Pharm Clin. 2000;19:137–42.

Gillings N, Hjelstuen O, Ballinger J, Behe M, Decristoforo C, Elsinga P, et al. Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. EJNMMI Radiopharm Chem. 2021;6:8.

Mattner F, Gastmeier P. Bacterial contamination of multiple-dose vials: a prevalence study. Am J Infect Control. 2004;32:12–6.

Radiopharmaceutical preparation—European Pharmacopoeia 11.0 n.d. [cited 2023 March 2]. Available from: https://pheur.edqm.eu/app/11-0/content/11-0/0125E.html.

Silberstein EB. Prevalence of adverse events to radiopharmaceuticals from 2007 to 2011. J Nucl Med. 2014;55:1308–10.

Snowdon GM. Is your technetium generator eluate sterile? J Nucl Med Technol. 2000;28:94–5.

2.6.1. Sterility–European Pharmacopoeia 11.0. [cited 2023 Apr 13]. Available from: https://pheur.edqm.eu/app/11-0/content/11-0/20601E.htm?highlight=on&terms=sterility.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Thông tin tác giả